The U.S. Food and Drug Administration (FDA) announced that it will fast-track review of nine experimental drugs.

Your prescription may be involved. The FDA explains why suddenly stopping your medication is more harmful than taking it.

The Food and Drug Administration is announcing the first round of drugs that will receive drastically expedited reviews at the agency

The winners include a gene therapy for a rare form of deafness, a drug for vaping addiction, and a generic antibiotic.

Amid the chaos of the Trump administration’s haphazard job cuts and a mass exodus of leadership, the Food and Drug Administration is experiencing a slowdown of drug reviews and approvals, according to an analysis reported by Stat News.

FDA announces Atorvastatin recall affecting over 140,000 bottles of cholesterol medication due to failed dissolution specs that could reduce effectiveness.

This recall comes amid growing concerns about the safety of raw pet food, as salmonella contamination poses serious health risks not only to animals but also to humans who handle contaminated food or come into contact with infected pets.

FDA approves Bayer’s Lynkuet, a first-of-its-kind non-hormonal pill to treat moderate to severe menopausal hot flashes by blocking NK1/NK3 receptors.

The Food and Drug Administration granted orphan drug designation to Revolution Medicines' treatment for pancreatic cancer. The drug, called daraxonrasib, is being studied in a global phase three clinical trial and the company is planning to begin two more phase three trials for the drug.

A health insurance dispute is preventing a North Carolina man from getting a cancer drug his doctors say is necessary.

CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall Survival